Cullen Frost Bankers Inc. lifted its stake in shares of Elanco Animal Health (NYSE:ELAN) by 40.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 213,638 shares of the company’s stock after purchasing an additional 62,042 shares during the period. Cullen Frost Bankers Inc.’s holdings in Elanco Animal Health were worth $6,291,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. lifted its stake in Elanco Animal Health by 4.7% in the second quarter. BlackRock Inc. now owns 20,483,172 shares of the company’s stock valued at $692,331,000 after purchasing an additional 924,059 shares during the last quarter. State Street Corp raised its stake in shares of Elanco Animal Health by 4.1% in the fourth quarter. State Street Corp now owns 10,167,561 shares of the company’s stock valued at $299,435,000 after buying an additional 404,210 shares during the period. Sound Shore Management Inc. CT raised its stake in shares of Elanco Animal Health by 2.6% in the fourth quarter. Sound Shore Management Inc. CT now owns 3,568,060 shares of the company’s stock valued at $105,079,000 after buying an additional 91,580 shares during the period. California Public Employees Retirement System raised its stake in shares of Elanco Animal Health by 1.4% in the fourth quarter. California Public Employees Retirement System now owns 1,437,010 shares of the company’s stock valued at $42,320,000 after buying an additional 19,571 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Elanco Animal Health by 0.6% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,393,520 shares of the company’s stock valued at $41,039,000 after buying an additional 7,999 shares during the last quarter. Institutional investors own 99.08% of the company’s stock.

In related news, Director John P. Bilbrey purchased 3,766 shares of Elanco Animal Health stock in a transaction dated Friday, November 22nd. The stock was bought at an average cost of $26.58 per share, for a total transaction of $100,100.28. Following the completion of the transaction, the director now owns 2,783 shares in the company, valued at $73,972.14. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.04% of the stock is owned by company insiders.

ELAN has been the subject of several research reports. Gabelli reiterated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, January 14th. Morgan Stanley upgraded Elanco Animal Health from an “equal” rating to an “equal weight” rating and lowered their price objective for the company from $34.00 to $32.00 in a research note on Thursday, November 7th. UBS Group lowered their price objective on Elanco Animal Health from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Raymond James started coverage on shares of Elanco Animal Health in a report on Thursday, January 9th. They set a “market perform” rating on the stock. Finally, ValuEngine lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating in a research report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $33.83.

NYSE:ELAN opened at $31.12 on Friday. The company has a market cap of $11.66 billion, a P/E ratio of 119.70, a P/E/G ratio of 2.96 and a beta of 0.73. The stock’s fifty day moving average price is $30.33 and its two-hundred day moving average price is $28.43. Elanco Animal Health has a 1 year low of $25.25 and a 1 year high of $35.46. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.12 and a quick ratio of 1.67.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Further Reading: What are the qualifications of a portfolio manager?

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.